← Eichor
Study identifier: NCT06313645 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Vascular Senescence and Atherosclerotic Plaque Vulnerability

Condition: Coronary Artery Disease  ·  Sponsor: Niguarda Hospital

PhaseN/A
Planned participants300
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Chronological aging significantly contributes to structural and functional alterations in the vasculature, making it a major risk factor for atherosclerotic disease and its acute thrombotic events. DNA damage, including telomeric, non-telomeric, and mitochondrial damage, is recognized as a key initiator of vascular aging and atherogenesis. There is abundant evidence indicating the presence of oxidative DNA lesions, telomere erosion, and mitochondrial DNA damage in both experimental and human plaques, as well as in the peripheral cells of atherosclerotic patients. It is increasingly evident that genomic instability activates signaling pathways that lead to a multitude of pathophysiological cellular and molecular changes. These changes promote inflammation, apoptosis, autophagy, and ultimately, cellular senescence, accompanied by the "senescence-associated secretory phenotype" (SASP). However, the precise mechanisms linking the DNA damage response (DDR) to senescence, SASP in vascular cells, and the pathogenesis of atherosclerosis and vulnerable atheroma are yet to be fully understood. Additional research is needed to delineate the underlying mechanisms through which mitochondrial dysfunction influences telomere length and vice versa, and how their interaction contributes to the vascular aging process. Progress in this area has the potential to uncover therapeutic targets and novel, more precise diagnostic, and prognostic indicators. The objectives of the VICTORIA study are t…

This description comes directly from the study's public registry record.

Talk to the study team

Jonica Campolo, MSc  ·  +39026444  ·  jonica.campolo@ospedaleniguarda.it

Emanuela Piccaluga, MD  ·  +39026444  ·  emanuela.piccaluga@ospedaleniguarda.it

Always discuss trial participation with your own doctor first.

Locations (1)

ASST GOM NiguardaMilan, Lombardy, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06313645